Use of biomarkers for diagnostics, monitoring of disease progression, investigation of pathogenesis, and therapy control in neuroinflammatory, neurometabolic, neuromuscular, and neurodegenerative diseases in childhood and adolescence. Subproject: Extracellular vesicles

Use of biomarkers for diagnostics, monitoring of disease progression, investigation of pathogenesis, and therapy control in neuroinflammatory, neurometabolic, neuromuscular, and neurodegenerative diseases in childhood and adolescence. Subproject: Extracellular vesicles - EV-Biomarker-pMS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035289

Enrollment

Registered

2024-10-17

Start date

2024-10-21

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G35.10

Interventions

Group 1: Extracellular vesicles out of blood plasma from pediatric multiple sclerosis patients at the age of 10 - 18 years will be isolated and analyzed Group 2: Extracellular vesicles out of blood

Eligibility

Sex/Gender

All

Age

10 Years to 18 Years

Inclusion criteria

Inclusion criteria: pediatric multiple sclerosis patients and healthy controls

Exclusion criteria

Exclusion criteria: Relapse in 3 months before inclusion; severe diseases that cause brain atrophy; psychiatric or neurological diseases or symptoms that are not associated with MS

Design outcomes

Primary

Measure	Time frame
Molecular processes that lead to neurodegeneration and regeneration in pediatric multiple sclerosis will be identified	—

Countries

Germany

Contacts

Public ContactKolja Meier

Universitätsmedizin Göttingen, Klinik für Kinder- und Jugendmedizin

kolja.meier@med.uni-goettingen.de+495513967670

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026